<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00714259</url>
  </required_header>
  <id_info>
    <org_study_id>F080429003</org_study_id>
    <secondary_id>UAB-0775</secondary_id>
    <nct_id>NCT00714259</nct_id>
  </id_info>
  <brief_title>Non-Myeloablative Allogeneic HSCT From HLA Matched Related or Unrelated Donors for the Treatment of Low Grade B Cell Malignancies</brief_title>
  <official_title>UAB 0775 Phase II Trial of Non-Myeloablative Allogeneic Hematopoietic Cell Transplantation Protocol From HLA Matched Related Donors for The Treatment of Patients With Low Grade B Cell Malignancies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Alabama at Birmingham</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Alabama at Birmingham</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A non-myeloablative treatment strategy and uniform selection criteria will enable patients
      with a variety of low grade B-Cell malignancies to attain long term disease control without
      unacceptably high treatment related mortality.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Non myeloablative transplant aims to achieve the immunological advantage of graft versus
      tumor effect as conventional myeloablative therapy without causing high treatment related
      toxicities. Non myeloablative transplant has been gaining wider acceptance as a way to
      achieve longer disease free and over all survival in patients with low grade B-cell
      malignancies, which otherwise is an incurable disease. Recent studies of non-myeloablative
      HSCT have demonstrated the powerful effect of graft versus leukemia alone against myeloma and
      other malignant B-cell malignancies if the transplant is performed for low grade, low volume
      disease.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Accrual goals could not be met within a timely manner
  </why_stopped>
  <start_date>July 2008</start_date>
  <completion_date type="Actual">February 2013</completion_date>
  <primary_completion_date type="Actual">February 2013</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progressive Free Survival Post Transplant</measure>
    <time_frame>100 days post transplant</time_frame>
    <description>subjects surviving without disease progression at 100 days after transplant as evidenced by decreased disease and no new disease showing on radiologic scans and / or bone marrow pathology.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Progressive Free Survival Post Transplant</measure>
    <time_frame>180 days post transplant</time_frame>
    <description>Subjects surviving without disease progression 180 days after transplant as evidenced by decreased disease and no new disease showing on radiologic scans and / or bone marrow pathology.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Progressive Free Survival Post Transplant</measure>
    <time_frame>365 days post transplant</time_frame>
    <description>Subjects surviving without disease progression 365 days after transplant as evidenced by decreased disease and no new disease showing on radiologic scans and / or bone marrow pathology.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Progression Free Survival Post Transplant</measure>
    <time_frame>2 years post transplant</time_frame>
    <description>Subjects surviving without disease progression 2 years after transplant as evidenced by no new disease showing on radiologic scans and / or bone marrow pathology.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Non-relapse Treatment Related Mortality</measure>
    <time_frame>Within 100 days post transplant</time_frame>
    <description>Death related to treatment without relapse within 100 days after transplant</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Detectable Donor Chimerism at up to 100 Days Post Transplant</measure>
    <time_frame>Post transplant up to 100 days post transplant</time_frame>
    <description>Measured by number of participants that have chimerism study results that show the number of donor cells and the number of recipient cells present in the blood after post-transplant lymphocyte infusions continue to be predominately either donor or recipient.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Composite Incidence of Acute and Chronic Graft Versus Host Disease</measure>
    <time_frame>Up to 100 days post transplant.</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">5</enrollment>
  <condition>Multiple Myeloma</condition>
  <condition>CLL / SLL</condition>
  <condition>Non Hodgkin's Lymphoma</condition>
  <condition>Waldenstroms</condition>
  <condition>Mantle Cell Lymphoma</condition>
  <arm_group>
    <arm_group_label>Non Myeloablative Treatment</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Non-myeloablative Transplant Conditioning Chemotherapy :
Fludarabine - 30 mg/m2/day x 3 days Total Body Irradiation - 200cGy x1 dose Infusion of Stem Cells - On Day 0 pts will received an infusion of HLA matched sibling donor stem cells. Dose is determined by the volume of cells obtained from donor. Minimum dose is 2x10*6 CD34+ cells per kilogram of recipient weight.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fludarabine</intervention_name>
    <description>Fludarabine 30 mg/m2/day x 3 days</description>
    <arm_group_label>Non Myeloablative Treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Total Body Irradiation</intervention_name>
    <description>TBI 200cGy x1 dose on transplant day</description>
    <arm_group_label>Non Myeloablative Treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Infusion of Stem Cells</intervention_name>
    <description>On Day 0 pts will received an infusion of HLA matched sibling donor stem cells. Dose is determined by the volume of cells obtained from donor. Minimum dose is 2x10*6 CD34+ cells per kilogram of recipient weight.</description>
    <arm_group_label>Non Myeloablative Treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Stage II or III non-progressive disease Multiple Myeloma.

          -  CLL/SLL, and low grade Hodgkin Lymphomas that are in a very good partial response or
             complete response with non-progressive disease.

          -  ≤ 70 years old.

          -  Eligible and willing HLA matched related donor.

          -  Bilirubin &lt;2xULN.

          -  ALT and AST &lt;3xULN.

          -  LVEF &gt; 40%.

          -  Creatinine Clearance &gt;40mL/min.

          -  Pulmonary function DLCO corrected to ≥ 70%.

          -  Minimum performance score of 70%.

          -  Platelet count &gt;130 x103 micro L.

          -  LDH ≤1.5xULN.

          -  No proceeding co-morbid condition that significantly increases the risk of severe
             regimen related toxicity.

          -  No uncontrolled infections.

        Exclusion Criteria:

          -  Age &gt;70 years old.

          -  Performance status &lt;70%.

          -  Uncontrolled infections or is HIV positive

          -  Prior malignancies that are felt to have a &lt;80% probability of being cured.

          -  Pregnant, breastfeeding, or refuse to use contraceptive techniques during and for 12
             months following transplant.

          -  Prior Allograft

          -  History of rapidly growing disease at diagnosis or at any progression or have MDS.

          -  No eligible and willing HLA matched donor.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>William P. Vaughan, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Alabama in Birmingham</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Alabama in Birmingham BMT/CT Program Outpatient Clinic</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35249-6979</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 10, 2008</study_first_submitted>
  <study_first_submitted_qc>July 11, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 14, 2008</study_first_posted>
  <results_first_submitted>November 5, 2015</results_first_submitted>
  <results_first_submitted_qc>March 23, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">May 4, 2017</results_first_posted>
  <last_update_submitted>June 22, 2017</last_update_submitted>
  <last_update_submitted_qc>June 22, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 24, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Alabama at Birmingham</investigator_affiliation>
    <investigator_full_name>Racquel Innis-Shelton, MD</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Low Grade B Cell Malignancies</keyword>
  <keyword>nonmyeloablative transplant</keyword>
  <keyword>allogeneic</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
    <mesh_term>Lymphoma, Mantle-Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fludarabine</mesh_term>
    <mesh_term>Fludarabine phosphate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Single Arm Trial</title>
          <description>Single Arm Intervention trial as noted in interventions section
Fludarabine: Fludarabine 30 mg/m2/day x 3 days
Total Body Irradiation: TBI 200cGy x1 dose on transplant day
Infusion of Stem Cells: On Day 0 pts will received an infusion of HLA matched sibling donor stem cells. Dose is determined by the volume of cells obtained from donor. Minimum dose is 2x10*6 CD34+ cells per kilogram of recipient weight.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Single Arm Trial</title>
          <description>Single Arm Intervention trial as noted in interventions section
Fludarabine: Fludarabine 30 mg/m2/day x 3 days
Total Body Irradiation: TBI 200cGy x1 dose on transplant day
Infusion of Stem Cells: On Day 0 pts will received an infusion of HLA matched sibling donor stem cells. Dose is determined by the volume of cells obtained from donor. Minimum dose is 2x10*6 CD34+ cells per kilogram of recipient weight.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="5"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Progressive Free Survival Post Transplant</title>
        <description>subjects surviving without disease progression at 100 days after transplant as evidenced by decreased disease and no new disease showing on radiologic scans and / or bone marrow pathology.</description>
        <time_frame>100 days post transplant</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Single Arm Trial</title>
            <description>Single Arm Intervention trial as noted in interventions section
Fludarabine: Fludarabine 30 mg/m2/day x 3 days
Total Body Irradiation: TBI 200cGy x1 dose on transplant day
Infusion of Stem Cells: On Day 0 pts will received an infusion of HLA matched sibling donor stem cells. Dose is determined by the volume of cells obtained from donor. Minimum dose is 2x10*6 CD34+ cells per kilogram of recipient weight.</description>
          </group>
        </group_list>
        <measure>
          <title>Progressive Free Survival Post Transplant</title>
          <description>subjects surviving without disease progression at 100 days after transplant as evidenced by decreased disease and no new disease showing on radiologic scans and / or bone marrow pathology.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Non-relapse Treatment Related Mortality</title>
        <description>Death related to treatment without relapse within 100 days after transplant</description>
        <time_frame>Within 100 days post transplant</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Single Arm Trial</title>
            <description>Single Arm Intervention trial as noted in interventions section
Fludarabine: Fludarabine 30 mg/m2/day x 3 days
Total Body Irradiation: TBI 200cGy x1 dose on transplant day
Infusion of Stem Cells: On Day 0 pts will received an infusion of HLA matched sibling donor stem cells. Dose is determined by the volume of cells obtained from donor. Minimum dose is 2x10*6 CD34+ cells per kilogram of recipient weight.</description>
          </group>
        </group_list>
        <measure>
          <title>Non-relapse Treatment Related Mortality</title>
          <description>Death related to treatment without relapse within 100 days after transplant</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Detectable Donor Chimerism at up to 100 Days Post Transplant</title>
        <description>Measured by number of participants that have chimerism study results that show the number of donor cells and the number of recipient cells present in the blood after post-transplant lymphocyte infusions continue to be predominately either donor or recipient.</description>
        <time_frame>Post transplant up to 100 days post transplant</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Single Arm Trial</title>
            <description>Single Arm Intervention trial as noted in interventions section
Fludarabine: Fludarabine 30 mg/m2/day x 3 days
Total Body Irradiation: TBI 200cGy x1 dose on transplant day
Infusion of Stem Cells: On Day 0 pts will received an infusion of HLA matched sibling donor stem cells. Dose is determined by the volume of cells obtained from donor. Minimum dose is 2x10*6 CD34+ cells per kilogram of recipient weight.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Detectable Donor Chimerism at up to 100 Days Post Transplant</title>
          <description>Measured by number of participants that have chimerism study results that show the number of donor cells and the number of recipient cells present in the blood after post-transplant lymphocyte infusions continue to be predominately either donor or recipient.</description>
          <units>participant</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Composite Incidence of Acute and Chronic Graft Versus Host Disease</title>
        <time_frame>Up to 100 days post transplant.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Single Arm Trial</title>
            <description>Single Arm Intervention trial as noted in interventions section
Fludarabine: Fludarabine 30 mg/m2/day x 3 days
Total Body Irradiation: TBI 200cGy x1 dose on transplant day
Infusion of Stem Cells: On Day 0 pts will received an infusion of HLA matched sibling donor stem cells. Dose is determined by the volume of cells obtained from donor. Minimum dose is 2x10*6 CD34+ cells per kilogram of recipient weight.</description>
          </group>
        </group_list>
        <measure>
          <title>Composite Incidence of Acute and Chronic Graft Versus Host Disease</title>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Progressive Free Survival Post Transplant</title>
        <description>Subjects surviving without disease progression 180 days after transplant as evidenced by decreased disease and no new disease showing on radiologic scans and / or bone marrow pathology.</description>
        <time_frame>180 days post transplant</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Single Arm Trial</title>
            <description>Single Arm Intervention trial as noted in interventions section
Fludarabine: Fludarabine 30 mg/m2/day x 3 days
Total Body Irradiation: TBI 200cGy x1 dose on transplant day
Infusion of Stem Cells: On Day 0 pts will received an infusion of HLA matched sibling donor stem cells. Dose is determined by the volume of cells obtained from donor. Minimum dose is 2x10*6 CD34+ cells per kilogram of recipient weight.</description>
          </group>
        </group_list>
        <measure>
          <title>Progressive Free Survival Post Transplant</title>
          <description>Subjects surviving without disease progression 180 days after transplant as evidenced by decreased disease and no new disease showing on radiologic scans and / or bone marrow pathology.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Progressive Free Survival Post Transplant</title>
        <description>Subjects surviving without disease progression 365 days after transplant as evidenced by decreased disease and no new disease showing on radiologic scans and / or bone marrow pathology.</description>
        <time_frame>365 days post transplant</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Single Arm Trial</title>
            <description>Single Arm Intervention trial as noted in interventions section
Fludarabine: Fludarabine 30 mg/m2/day x 3 days
Total Body Irradiation: TBI 200cGy x1 dose on transplant day
Infusion of Stem Cells: On Day 0 pts will received an infusion of HLA matched sibling donor stem cells. Dose is determined by the volume of cells obtained from donor. Minimum dose is 2x10*6 CD34+ cells per kilogram of recipient weight.</description>
          </group>
        </group_list>
        <measure>
          <title>Progressive Free Survival Post Transplant</title>
          <description>Subjects surviving without disease progression 365 days after transplant as evidenced by decreased disease and no new disease showing on radiologic scans and / or bone marrow pathology.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Progression Free Survival Post Transplant</title>
        <description>Subjects surviving without disease progression 2 years after transplant as evidenced by no new disease showing on radiologic scans and / or bone marrow pathology.</description>
        <time_frame>2 years post transplant</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Single Arm Trial</title>
            <description>Single Arm Intervention trial as noted in interventions section
Fludarabine: Fludarabine 30 mg/m2/day x 3 days
Total Body Irradiation: TBI 200cGy x1 dose on transplant day
Infusion of Stem Cells: On Day 0 pts will received an infusion of HLA matched sibling donor stem cells. Dose is determined by the volume of cells obtained from donor. Minimum dose is 2x10*6 CD34+ cells per kilogram of recipient weight.</description>
          </group>
        </group_list>
        <measure>
          <title>Progression Free Survival Post Transplant</title>
          <description>Subjects surviving without disease progression 2 years after transplant as evidenced by no new disease showing on radiologic scans and / or bone marrow pathology.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Single Arm Trial</title>
          <description>Single Arm Intervention trial as noted in interventions section
Fludarabine: Fludarabine 30 mg/m2/day x 3 days
Total Body Irradiation: TBI 200cGy x1 dose on transplant day
Infusion of Stem Cells: On Day 0 pts will received an infusion of HLA matched sibling donor stem cells. Dose is determined by the volume of cells obtained from donor. Minimum dose is 2x10*6 CD34+ cells per kilogram of recipient weight.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>RSV pneumonia Infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Klebsiella pneumonia Infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <description>Pneumonia not otherwise specified</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>William Vaughan, MD</name_or_title>
      <organization>UAB</organization>
      <phone>20-934-0066</phone>
      <email>liwilliams@uabmc.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

